Can step counts predict treatment success in prostate cancer?

This study looks at whether daily step counts can help monitor how well vulnerable patients with metastatic hormone-sensitive prostate cancer are doing on a combination of darolutamide and standard hormone therapy. About 80 adults who are frail or have other health issues will wear a device to track their steps over 6 months. The goal is to see if changes in physical activity relate to side effects, quality of life, and overall treatment outcomes.